clinical trial · NCT05678673
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Exelixis·phase3·active not recruiting·n = 317
Non-Clear Cell Renal Cell CarcinomaXL092NivolumabSunitinib Malate
brief summary
This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.
started
Jan 1, 2023
primary completion
Jul 1, 2025
completion
Jun 1, 2028
last updated
Jul 14, 2025
official title
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol